BPC-157 (Oral Form)
Pending PCACAlso known as: BPC-157 capsule, Oral BPC-157, PL 14736
Healing & RecoveryLast reviewed: April 28, 2026
The oral formulation of BPC-157, distinct from the injectable form in its bioavailability profile and primary applications. While injectable BPC-157 is used for systemic and musculoskeletal healing, oral BPC-157 is particularly relevant for gastrointestinal conditions where direct gut exposure may be more important than systemic absorption.
Mechanism of Action
Same mechanism as injectable BPC-157 — promotes angiogenesis, upregulates growth factors, and modulates nitric oxide synthesis. In oral form, the peptide is exposed directly to the GI tract mucosa before any systemic absorption, potentially making it more effective for gut-specific conditions.
Common Uses
- Inflammatory bowel disease (IBD)
- Leaky gut and intestinal permeability
- NSAID-induced gastric damage
- Gut healing and GI protection
- Esophageal and stomach ulcers
Known Risks
- Lower and more variable systemic bioavailability than injectable
- Limited human clinical data for oral form specifically
- Quality of oral preparations varies significantly
- Long-term safety unknown
Regulatory Status
Shares the same regulatory status as injectable BPC-157 — removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 23, 2026. The oral form is particularly relevant for the FDA's listed indication of ulcerative colitis. Compounding not yet authorized.
Get notified when the PCAC decides on BPC-157 (Oral Form)
Scheduled review: July 23, 2026. We'll email you the same day results are announced.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Oral capsule
Typical Dose
250–500 mcg
Frequency
Once or twice daily, on empty stomach
Cycle Length
4–12 weeks
Take 30 minutes before meals for best gut exposure. For systemic effects (musculoskeletal), injectable form is preferred. For gut-specific conditions, oral may be equally or more effective.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.